ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ELTX Elicio Therapeutics Inc

8.41
-0.44 (-4.97%)
25 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Elicio Therapeutics Inc NASDAQ:ELTX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.44 -4.97% 8.41 4.99 50.00 8.85 7.49 8.78 52,950 05:00:09

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

05/02/2024 1:30pm

GlobeNewswire Inc.


Elicio Therapeutics (NASDAQ:ELTX)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more Elicio Therapeutics Charts.

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 12:40 PM ET.

A live webcast of the presentation will be accessible under “Events” in the Investors section of Elicio’s website and will be available on-demand for 90 days following the event.

About Elicio TherapeuticsElicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (“AMP”) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.

Media ContactKristin PolitiLifeSci Communicationskpoliti@lifescicomms.com646-876-4783

Investor Relations ContactHeather DiVecchiaElicio TherapeuticsIR@elicio.com857-209-0153

1 Year Elicio Therapeutics Chart

1 Year Elicio Therapeutics Chart

1 Month Elicio Therapeutics Chart

1 Month Elicio Therapeutics Chart

Your Recent History

Delayed Upgrade Clock